Takeda Gives UK’s NICE Economic Model Review Service Thumbs Up
Executive Summary
A new service provided by UK HTA body NICE for evaluating economic models that will be reviewed by health technology appraisal bodies has been a success, according to Takeda.
You may also be interested in...
UK Industry Raises Conflict of Interest Concerns Over NICE’s PRIMA Service
PRIMA, the new service the National Institute for Health and Care Excellence offers to review economic models, must not be affected by confidentiality and conflict of interest issues, warns UK the pharmaceutical industry group, ABPI.
UK’s NICE Aims To Knock Firms’ Health Economic Models Into Shape
The scientific advice department at UK HTA body NICE is offering a new peer-review service to companies that want to make sure their economic models are as watertight as possible for making submissions to health technology assessment agencies and payers. One pilot project has already taken place.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.